AIMS Programs: Next generation immune therapies endeavoring to deliver immune homeostasis
CYTO-200 AIMS™ Program
noroxymorphone-n-substituted-methyl cyclopropyl
Discovery | Lead Optimization | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | NDA |
CYTO-400 AIMS™ Program
Proenkephalin
Discovery | Lead Optimization | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | NDA |
CYTO-600 Program
TLR5 Platform
Discovery | Lead Optimization | Pre-Clinical | Pivotal Animal Studies | Human Safety / Dose Conversion |
Discovery | Lead Optimization | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | NDA |